CD34+/CD38- Stem Cell Burden Could Predict Chronic Myeloid Leukemia Patients' Outcome.

Noura Fathy El-MetwalySalah ArefMohamed AyedManal Abdel HamidAhmed M A El-Sokkary

Published in: Asian Pacific journal of cancer prevention : APJCP (2021)

The percentage of CD34+/CD38- SCs burden at diagnosis reflects the CML disease behavior and is considered a biomarker for predicting CML patients' response to first-line Tyrosine kinase inhibitors (TKI) therapy.

Keyphrases

chronic myeloid leukemia
end stage renal disease
stem cells
ejection fraction
chronic kidney disease
newly diagnosed
bone marrow
epidermal growth factor receptor